Advances in Oncogenic Evaluation and Nomenclature of Gene Fusions in Solid Tumors

Program Committee Moderator(s)

• 

  Arivarasan Karunamurthy

  Assistant Professor
  University of Pittsburgh Medical Center
  Pittsburgh, Pennsylvania, United States

Co-Moderator (Early Career)(s)

• PD

  Pranav Dorwal

Description: Recent advances in next-generation technologies have significantly improved the detection and reporting of gene fusions in tumors. However, the lack of standardized best practices for fusion detection methodologies, pathogenicity evaluation, and reporting, particularly remains a challenge. This session will delve into the biology and complexities of gene fusion, the use of bioinformatic tools for fusion detection and accurate classification, and the importance of standardized fusion nomenclature and reporting.

If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)

Title: Oncogenic RET Fusions: Biology, Testing, and Treatment
Please Click Here to Learn More.

Presentations:

• 10:15 AM - 10:45 AM EST

  Gene Fusions in Cancers: Challenges in Detection and Interpretation
  

  Breakout Speaker: Angshumoy Roy, MD, PhD (he/him/his) – Baylor College of Medicine / Texas Children’s Hospital
• 10:45 AM - 11:15 AM EST

  Current Standards for Classifying Fusion Oncogenicity and its Applications
  

  Breakout Speaker: Jason Saliba, PhD (he/him/his) – Washington University School of Medicine in St. Louis
• 11:15 AM - 11:45 AM EST

  Current Standards for Gene Fusion Nomenclature and Reporting
  

  Breakout Speaker: Karen Tsuchiya, MD (she/her/hers) – Institute for Genomic Medicine/Nationwide Children's Hospital